Shareholder Returns
Information on Sumitomo Pharma’s shareholder returns.
Dividend
As a result of expanding its existing product businesses and implementing a fundamental structural reform, including an early retirement program, Sumitomo Pharma achieved a positive core operating profit and net profit in the fiscal year ended March 2025. Furthermore, based on the "Reboot2027" announced in May 2025, which outlines the activity policy for FY2025 through FY2027, the Company will focus on early maximizing the value of three key products and pursuing thorough cost management aiming to maintain profitability in core operating profit and net profit. However, as the Company needs to prioritize the repayment of interest-bearing debt and improve financial soundness, the Company regrets to announce that dividends will be suspended for the fiscal year ending March 2026.
The Company would like to extend its deepest apologies to its shareholders. The Company remains committed to driving its business activities forward as a united organization, and would appreciate your understanding and continued support.
We have not split or consolidated our shares during the periods shown in the table below.
| FY2023 | FY2024 | FY2025 (tentative) | |
|---|---|---|---|
| Consolidated dividend payment ratio | ー | ー | ー |
Our basic policy on profit distribution
The Company believes it important to distribute surpluses in an appropriate manner reflecting any improvement in its performance. Accordingly, a performance-linked dividend hike will be considered in addition to consistent dividend payment.
| FY2023 | FY2024 | FY2025 (tentative) | |
|---|---|---|---|
| Dividend per share | 0yen | 0yen | 0yen |
Share repurchase
No share repurchase is currently taking place.
Shareholder incentives
No shareholder incentive program is currently taking place.